City of Hope | Strategic Alliance Partners

January 14, 2022

Alexey V. Danilov, MD, PhD, discusses the reduced use of chemoimmunotherapy in chronic lymphocytic leukemia.

January 13, 2022

Dr Basu discusses the “shadow curve” that could result from disruptions in cancer care during the COVID-19 pandemic and innovative strategies that Cancer Treatment Centers of America are taking to avoid this.

January 12, 2022

Cancer Treatment Centers of America's comprehensive cancer centers in Chicago and Atlanta earned the 2021 Guardian of Excellence Award from Press Ganey as top performers in patient experience.

January 10, 2022

It is difficult to know where exactly to begin this commentary regarding the FDA approval to permit commer-cial sales of the Alzheimer disease drug aducanumab-avwa.

December 23, 2021

Maurie Markman, MD on strategies to appropriately evaluate small but clinically relevant patient subsets for whom traditional phase 3 randomized clinical trials are difficult, if not impossible, to complete in a realistically timely manner.

December 21, 2021

Tanya Dorff, MD, discusses the clinical implications of the phase 3 ARAMIS trial in nonmetastatic castration-resistant prostate cancer.

November 19, 2021

The trial is the first in the world offering this City of Hope-developed investigational therapy to patients with the hope of one day improving survival for people with triple-negative breast cancer.

November 09, 2021

Katherine Poruk, MD, a board-certified and fellowship-trained surgical oncologist and researcher, is the latest addition to the Cancer Treatment Centers of America®, Atlanta, physician team.

November 01, 2021

Alexey V. Danilov, MD, PhD, discusses the rationale to target MCL1 and BCLX in chronic lymphocytic leukemia.

October 27, 2021

Danny Nguyen, MD, discusses management strategies for mobocertinib-related gastrointestinal toxicities in EGFR exon 20 insertion–positive non–small cell lung cancer.

October 25, 2021

Syed A. Abutalib, MD, associate medical director, Hematologic Malignancies and Stem Cell Transplant Program, Cancer Treatment Centers of America, discusses recent updates in chronic lymphocytic leukemia.

October 21, 2021

Alexey V. Danilov, MD, PhD, discusses the safety profile of entospletinib plus obinutuzumab in chronic lymphocytic leukemia.

October 21, 2021

The investigational NEDD8-activating enzyme inhibitor pevonedistat in combination with ibrutinib demonstrated high response rates with a tolerable safety profile in patients with relapsed/refractory chronic lymphocytic leukemia and mantle cell lymphoma.

October 14, 2021

Alexey V. Danilov, MD, PhD, discusses the rationale to combine entospletinib with obinutuzumab in relapsed/refractory chronic lymphocytic leukemia.

October 13, 2021

Alexey Danilov, MD, PhD, discussed the data on entospletinib/obinutuzumab in patients with R/R CLL and suggests further research directions with this drug combination.

October 13, 2021

Corepoint Integration Engine chosen to Streamline Connectivity Across Care Teams, Affiliate Networks, and Cancer Community, Extending Access to World-class Care for Patients Everywhere.

October 12, 2021

The continued uncertainties of the current and future status of the COVID-19 pandemic have resulted in a lack of trust in the authority of the scientific establishment in the United States, and elsewhere, as it operates during these difficult times.

September 20, 2021

Alex Herrera, MD, discusses the potential for CAR T-cell therapy in earlier lines of treatment for patients with diffuse large B-cell lymphoma.

September 15, 2021

CTCA leverages new CMS Conditions of Participation notification requirements as opportunity for innovation

September 11, 2021

Alexey V. Danilov, MD, PhD, discusses the need to identify novel pathways for targeted therapy in chronic lymphocytic leukemia.